IMMUNOCLIN CORP (IMCL)

0.16
OTC Markets
Prev Close 0.16
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.10 / 0.19
Exchange OTC Markets
Shares Outstanding 28.83B
Market Cap 4.58M
Div & Yield N.A. (N.A)

Waiting and Watching

Until the indicators offer a clearer picture of where we're headed, stocks will likely swing back and forth for a bit.

Friday's Health Winners & Losers

Dynavax rises on an upgrade.

'Fast Money' Recap 'Pops and Drops': Onyx Overwhelmed

'Fast Money' Recap 'Pops and Drops': Onyx Overwhelmed

The shares' tumble shows how much of a hit a biotech can take at once.

Do These Biotech Dogs Still Have Legs?

Do These Biotech Dogs Still Have Legs?

Three once-promising stocks have been hit hard recently, leaving few reasons to believe.

Thursday's Daily Blogwatch

Cramer talks oil, are men really more competative than women, and feng shui's bearish take on the market.

Wednesday's Daily Blog Watch

Wednesday's Daily Blog Watch

Cramer discusses Ambac Financial, and where do all the market results come from?

Thursday's Health Winners & Losers

Medicis Pharma falls on news of a regulatory decision.

Tomorrow's Headliners: Google

Also, David Peltier will tell you whether you should buy Albemarle.

Biotech Notebook: Pipex, Gilead, Biogen Idec.

Biotech Notebook: Pipex, Gilead, Biogen Idec.

Pipex CEO Kanzer takes shareholders down a familiar path.

Icahn Angles for Biogen Board Seats

Icahn Angles for Biogen Board Seats

Activist investor Carl Icahn has nominated three people to the company's board.

Biotech Notebook: ImClone, Genentech, Amylin

Biotech Notebook: ImClone, Genentech, Amylin

ImClone looks even more undervalued than it did three months ago.

Gearing Up For Biotech's Super Bowl

Gearing Up For Biotech's Super Bowl

A slew of big companies will make presentations at the JPMorgan Healthcare Conference.

Biotech Trial Dates to Watch in '08

Biotech Trial Dates to Watch in '08

Myriad Genetics and Dendreon are among those with major clinical trials next year.

Biotech Stocks Face Make-or-Break FDA Rulings

Biotech Stocks Face Make-or-Break FDA Rulings

Several drugmakers face key approval votes in 2008.

For Biotech Investors, ASCO's Now an Open Book

For Biotech Investors, ASCO's Now an Open Book

Responding to years of criticism, annual meeting abstracts will now be made available to all.

ImClone Swings to a Loss

ImClone Swings to a Loss

A $50 million litigation settlement hits third-quarter profits.

Wednesday's Health Winners & Losers

Bristol-Myers climbs on collaboration news.

Stock Upgrades, Downgrades from TheStreet.com Ratings

Stock Upgrades, Downgrades from TheStreet.com Ratings

Gerdau, ImClone, Microsemi and Linn Energy upgraded; Wesco downgraded.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Cardium Therapeutics climbs.

Erbitux Gets Label Update

The FDA approves a labeling update for the drug as a treatment for colon cancer.

Top 10 Stocks With Big Insider Buying, Buybacks

Top 10 Stocks With Big Insider Buying, Buybacks

Large repurchases put Tyco and United Tech on the list.

This Week's Barron's Roundup

This Week's Barron's Roundup

Fund manager Jim Margard's large-cap picks, the latest insider purchases and a put-selling options play.

Ahead of Big Week, Bulls Make a Stand

Major averages shake off a slew of negatives. Stephen Porpora and Joe Capone handicap what should be a very volatile, dramatic week.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

Neurogen rises on a new CEO appointment.

Bulls on Parade as Fundamentals Matter

Good news from a number of firms sends shares sharply higher. Chris Edmonds opines on OPEC's surprise, plus Adam Feuerstein on ImClone, Amgen and biotech.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Corcept Pharma climbs on news of an investigational new-drug application from the FDA for Corlux.

ImClone's Future Gets Brighter

ImClone's Future Gets Brighter

Moving its Eribitux drug into lung cancer treatment would spark a jump in profit.

Sales Beef Up McD's Stock

Sales Beef Up McD's Stock

Shares rise on the latest comparable sales from August.

ImClone Soars on Erbitux Study Results

ImClone Soars on Erbitux Study Results

A large phase III study shows the drug prolonging survival in lung cancer patients.

Tuesday's Analysts' Upgrades and Downgrades

Tuesday's Analysts' Upgrades and Downgrades

Who made what calls.